Ameliorative Effect of Pentoxifylline a Phosphodiesterase-5 on Acrolein Induced Oxidative Damage

Background: Pentoxifylline (PTX), a methylxanthine derivative and nonspecific type 5 phosphodiesterase (PDE) inhibitor, is a drug widely used in the management of peripheral arterial disease. Objectives: The aim of this study was to investigate the possible protective role of PTX on toxicity of acrolein (ACR). Materials and Methods: In this experimental study, 30 male rats were equally divided in to 6 groups (5 rats each). Group I (control) that received normal saline, group II was given ACR (2 mg /kg/day, i.p.). Animals of group III received only PTX (50 mg/kg/day, i.p.). Group IV was given ACR + PTX, groups V received only vitamin E (15 mg/kg/day, s.c.) and group VI was given vitamin E combination to ACR once daily for 14 dayes. Oxidative damage were measured by oxidative biomarkers such as glutathione peroxidase (GPx), superoxide dismutase (SOD), lipid peroxidation (LPO) and total glutathione (GSH) in blood of rats. Results: At the end of the experiment, the plasma of the animals was separated. In the blood plasma, ACR reduced total glutathione (GSH), SOD and GPx compared control group. Also, the LPO was increased in the ACR group as compared with controls. PTX ameliorated LPO, SOD and GPx in blood of ACR-induced changes. Conclusions: These findings suggest that PTX may provide a promising approach for the treatment of ACR-related diseases throughout reduction oxidative injuries.